retatrutide trials weight loss (“reta”) is an experimental weight-loss drug currently in Phase 3 clinical trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works Retatrutide: The Breakthrough Shot Revolutionizing

Management of diabetic retinopathy requires concurrent management of diabetes and other systemic parameters

But the glucagon receptor is where retatrutide truly separates itself

doi: 10.3389/fendo.2021.721135 Received 06 June 2021 Accepted 05 August 2021 Published 23 August 2021 Volume 12 - 2021 Edited by Kazunori Sango, Tokyo Metropolitan Institute of Medical Science, Japan Reviewed by Mohammad Qaddoumi, Kuwait University, Kuwait

Fighting a digital hydra The Pharmaceutical Task Group , an industry body representing organised pharmacy and manufacturing interests, views this underground trade as a direct violation of the laws protecting the South African public

As obesity management continues to evolve, retatrutide may help redefine expectations for both weight reduction and metabolic health outcomes

Governance insight: The expansion of GLP-1 indicationsfrom diabetes to obesity to cardiovascular protection to sleep apnea to liver diseasewill increasingly challenge the artificial distinction between "covered" and "excluded" uses